Valuation as at 2026-08-04 · refreshed with the S&P 500 Most Undervalued screen
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Source: Yahoo Finance company profile · factual description, not KashVector commentary
Merck & Co., Inc. MRK
Healthcare · Drug Manufacturers - General
MRK's price & financial trends
Quarterly reporting periods — the most granular consistent series Yahoo provides for this market.
Data refreshed 2026-08-04
Share price · last 2 years
Earnings per share (diluted)
Free cash flow
Dividend per share
Intrinsic value estimate · 5-year forecast
Assumptions used in this valuation
Every input below is either fetched live from Yahoo Finance or a documented default — nothing is hidden.
| Bear | Base | Bull | |
|---|---|---|---|
| 5-yr FCF growth | 2.5% | 4.9% | 7.4% |
| Terminal growth | 2.5% | 2.5% | 2.5% |
| WACC (discount rate) | 6.62% | 5.62% | 4.62% |
Cost of Equity = Risk-free rate + Beta × Equity Risk Premium = 4.75% + 0.21 × 5.50% = 5.91% · WACC = weighted by 87%/13% capital structure
These numbers come from running Merck & Co., Inc.'s cash flows through the mechanical DCF formula and assumptions above — not from any view on the news, management, or MRK's competitive position. What is DCF?
Want to test your own growth or discount-rate assumptions?Open the full interactive calculator, pre-filled with MRK →
More S&P 500 Most Undervalued stocks
Not financial advice. DCF valuations are highly sensitive to assumptions — small changes in growth rate or discount rate produce large swings in output. This is a mechanical calculation, not a recommendation to buy, hold, or sell.
About this valuation
Refreshed on the same cycle as the S&P 500 Most Undervalued screen. Change any assumption yourself in the full interactive tool.
Frequently asked questions
Is MRK undervalued?
The Base-case DCF estimates intrinsic value at $191.20 vs a current price of $127.77 — a +49.6% margin, so the Base case reads undervalued. This is a mechanical output, not advice.